Prevention of Acute Kidney Injury in Patients With NSTEMI

PHASE2TerminatedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

April 21, 2021

Primary Completion Date

April 28, 2023

Study Completion Date

April 28, 2023

Conditions
Non-ST Elevation Myocardial Infarction (NSTEMI)
Interventions
DRUG

conestat alfa or placebo

"Conestat alfa will be dosed by body weight at 50 U/kg (maximum 4200 U) or 100 U/kg (maximum 8400 U).~Placebo will consist of normal saline (NaCl 0.9%). The interventions will be given to the patients by IV-line."

Trial Locations (4)

1205

University Hospital Geneva, Geneva

3010

Inselspital Bern, Bern

4031

University Hospital Basel, Basel

6900

Fondazione Istituto Cardiocentro Ticino, Lugano

Sponsors
All Listed Sponsors
lead

Pharming Technologies B.V.

INDUSTRY

NCT04912141 - Prevention of Acute Kidney Injury in Patients With NSTEMI | Biotech Hunter | Biotech Hunter